JP2022516557A5 - - Google Patents

Info

Publication number
JP2022516557A5
JP2022516557A5 JP2021538982A JP2021538982A JP2022516557A5 JP 2022516557 A5 JP2022516557 A5 JP 2022516557A5 JP 2021538982 A JP2021538982 A JP 2021538982A JP 2021538982 A JP2021538982 A JP 2021538982A JP 2022516557 A5 JP2022516557 A5 JP 2022516557A5
Authority
JP
Japan
Prior art keywords
antigen
binding domain
domain binds
cancer
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021538982A
Other languages
English (en)
Japanese (ja)
Other versions
JP7594161B2 (ja
JP2022516557A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/012296 external-priority patent/WO2020146221A1/en
Publication of JP2022516557A publication Critical patent/JP2022516557A/ja
Publication of JP2022516557A5 publication Critical patent/JP2022516557A5/ja
Priority to JP2024185692A priority Critical patent/JP2025013911A/ja
Application granted granted Critical
Publication of JP7594161B2 publication Critical patent/JP7594161B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021538982A 2019-01-07 2020-01-06 修飾il-2ポリペプチドを含むポリペプチド及びその使用 Active JP7594161B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024185692A JP2025013911A (ja) 2019-01-07 2024-10-22 修飾il-2ポリペプチドを含むポリペプチド及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962789075P 2019-01-07 2019-01-07
US62/789,075 2019-01-07
PCT/US2020/012296 WO2020146221A1 (en) 2019-01-07 2020-01-06 Polypeptides comprising modified il-2 polypeptides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024185692A Division JP2025013911A (ja) 2019-01-07 2024-10-22 修飾il-2ポリペプチドを含むポリペプチド及びその使用

Publications (3)

Publication Number Publication Date
JP2022516557A JP2022516557A (ja) 2022-02-28
JP2022516557A5 true JP2022516557A5 (cg-RX-API-DMAC7.html) 2023-01-19
JP7594161B2 JP7594161B2 (ja) 2024-12-04

Family

ID=69374426

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021538982A Active JP7594161B2 (ja) 2019-01-07 2020-01-06 修飾il-2ポリペプチドを含むポリペプチド及びその使用
JP2024185692A Pending JP2025013911A (ja) 2019-01-07 2024-10-22 修飾il-2ポリペプチドを含むポリペプチド及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024185692A Pending JP2025013911A (ja) 2019-01-07 2024-10-22 修飾il-2ポリペプチドを含むポリペプチド及びその使用

Country Status (15)

Country Link
US (1) US20220089667A1 (cg-RX-API-DMAC7.html)
EP (1) EP3908596A1 (cg-RX-API-DMAC7.html)
JP (2) JP7594161B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210113265A (cg-RX-API-DMAC7.html)
CN (1) CN113924311A (cg-RX-API-DMAC7.html)
AR (1) AR117770A1 (cg-RX-API-DMAC7.html)
AU (2) AU2020206672B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021012294A2 (cg-RX-API-DMAC7.html)
CA (1) CA3125529A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001779A1 (cg-RX-API-DMAC7.html)
IL (1) IL284633A (cg-RX-API-DMAC7.html)
MX (1) MX428580B (cg-RX-API-DMAC7.html)
SG (1) SG11202106700WA (cg-RX-API-DMAC7.html)
TW (1) TWI874345B (cg-RX-API-DMAC7.html)
WO (1) WO2020146221A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101520534B1 (ko) 2012-05-07 2015-05-21 고려대학교 산학협력단 말초혈액단핵구 유래 자연 살해세포의 유도 및 증식 방법
IL321812A (en) 2017-08-03 2025-08-01 Synthorx Inc Cytokine complexes for the treatment of autoimmune diseases
CN115710576A (zh) 2018-02-01 2023-02-24 Nkmax有限公司 产生天然杀伤细胞的方法和用于治疗癌症的组合物
TW202031284A (zh) 2018-11-08 2020-09-01 美商新索思股份有限公司 介白素10結合物及其用途
MA54952A (fr) 2019-02-06 2022-05-11 Synthorx Inc Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
CA3148135A1 (en) 2019-08-23 2021-03-04 Carolina E. CAFFARO Il-15 conjugates and uses thereof
WO2021050554A1 (en) 2019-09-10 2021-03-18 Synthorx, Inc. Il-2 conjugates and methods of use to treat autoimmune diseases
CN115916831A (zh) * 2020-06-30 2023-04-04 Gi 医诺微新 包含抗lag-3抗体和il-2的融合蛋白及其用途
EP4175979A2 (en) * 2020-07-02 2023-05-10 Inhibrx, Inc. Polypeptides comprising modified il-2 polypeptides and uses thereof
KR20230112632A (ko) 2020-10-23 2023-07-27 애셔 바이오테라퓨틱스, 인크. 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
WO2022099090A1 (en) * 2020-11-06 2022-05-12 Xencor, Inc. Heterodimeric antibodies that bind tgfbrii
EP4251187A4 (en) 2020-11-25 2025-09-10 Xilio Dev Inc TUMOR-SPECIFIC CLASSIBLE LINKERS
JP2023553216A (ja) * 2020-12-09 2023-12-20 アシャ バイオセラピューティクス,インク. 遺伝子操作細胞療法のための標的化サイトカイン構築物
CN112979782B (zh) * 2021-03-08 2023-07-18 深圳市乐土生物医药有限公司 一种多肽及其用途
CA3213751A1 (en) * 2021-03-31 2022-10-06 Ziyang Zhong Fusion proteins, pharmaceutical compositions, and therapeutic applications
TW202321283A (zh) * 2021-07-20 2023-06-01 美商英伊布里克斯公司 Cd8結合多肽及其用途
TW202309102A (zh) * 2021-07-20 2023-03-01 美商英伊布里克斯公司 靶向cd8之經修飾il-2多肽及其用途
TW202319397A (zh) * 2021-08-30 2023-05-16 美商英伊布里克斯公司 NKp46結合多肽及其用途
TW202328171A (zh) * 2021-08-30 2023-07-16 美商英伊布里克斯公司 靶向NKp46之經修飾之IL-2多肽及其用途
JP2024536840A (ja) * 2021-09-26 2024-10-08 ウーシー バイオロジクス アイルランド リミテッド Il-2バリアント及びその融合タンパク質
TW202334193A (zh) * 2022-01-05 2023-09-01 美商英伊布里克斯公司 靶向γδ T細胞之經修飾IL-2多肽及其用途
WO2024026449A2 (en) * 2022-07-28 2024-02-01 Proviva Therapeutics (Hong Kong) Limited Il-2 procytokine antibody fusion proteins
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
EP1454138B1 (en) * 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DK1678314T3 (da) 2003-10-22 2012-12-03 Keck Graduate Inst Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi
CN1930300A (zh) * 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
KR20070003934A (ko) * 2004-03-05 2007-01-05 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
CN102101885B (zh) 2010-09-01 2013-06-05 南京发士达生物科技有限公司 低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途
CN105440123B (zh) * 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
WO2013180200A1 (ja) * 2012-05-30 2013-12-05 中外製薬株式会社 標的組織特異的抗原結合分子
PT3102595T (pt) * 2014-02-06 2019-01-11 Hoffmann La Roche Proteínas de fusão de interleucina-2 e suas utilizações
IL304950A (en) 2015-04-10 2023-10-01 Amgen Inc Interleukin for the expansion of myotonic control T-2 cells
EP3402818A1 (en) * 2016-01-11 2018-11-21 Universität Zürich Combination therapy comprising a superagonistic antibody against interleukin-2 and a checkpoint blockade agent
KR20240115933A (ko) * 2016-05-04 2024-07-26 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
KR20240005989A (ko) * 2017-03-15 2024-01-12 큐 바이오파마, 인크. 면역 반응을 조절하는 방법
JP7148539B2 (ja) * 2017-04-03 2022-10-05 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 免疫抱合体
CA3052532A1 (en) * 2017-04-05 2018-10-11 F. Hoffmann-La Roche Ag Bispecific antibodies specifically binding to pd1 and lag3
AU2018273914A1 (en) * 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
AU2018287317B2 (en) * 2017-06-19 2024-06-20 Medicenna Therapeutics Inc. Uses and methods for IL-2 superagonists, agonists, and fusions thereof

Similar Documents

Publication Publication Date Title
JP2023532904A5 (cg-RX-API-DMAC7.html)
Chen et al. Bispecific antibodies in cancer immunotherapy
JP5851419B2 (ja) ヘテロダイマー結合タンパク質およびその使用
Weidle et al. Tumor-antigen–binding bispecific antibodies for cancer treatment
US11952421B2 (en) Bispecific antibodies against CD3EPSILON and ROR1
JP6702893B2 (ja) 多重特異的抗原結合タンパク質
Godar et al. Therapeutic bispecific antibody formats: a patent applications review (1994-2017)
FI3749346T3 (fi) Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät
US20220089722A1 (en) Heterodimeric fusion protein
CN115066274A (zh) 三价结合分子
JP2024534468A5 (cg-RX-API-DMAC7.html)
WO2023051727A1 (zh) 结合cd3的抗体及其用途
CA3125120A1 (en) Antibody fusion protein, preparation method therefor and application thereof
CN115836084A (zh) 多特异性免疫调节剂
JP2024521701A (ja) 抗cd137抗体及びその使用方法
JP2025504795A5 (cg-RX-API-DMAC7.html)
Brinkmann et al. The making of multispecific immunoglobulins–a clinical perspective
RU2021123226A (ru) Полипептиды, содержащие модифицированный полипептид il-2, и их применения
US20250376524A1 (en) Tetravalent multispecific binding molecules and methods of use thereof
WO2025201240A1 (en) Antibodies targeting cd3, cd28, and pd-l1 and uses thereof
WO2023199927A1 (ja) がん治療におけるpd-1シグナル阻害剤との組み合わせによる抗tspan8-抗cd3二重特異性抗体の使用
WO2025167357A1 (zh) Cd80/taa融合蛋白相关的肿瘤靶向、t细胞激活分子形式及其应用
WO2023219121A1 (ja) 抗taa-抗cd3多重特異性抗体
TW202434635A (zh) 多特異性抗體及其醫藥用途
KR20260062933A (ko) 항-γδ TCR 항체 및 이의 용도